In most cases, crypto prices perform well when the Fed and other central banks cut interest rates. Not this time... the latest crypto crash is bucking the trend.In most cases, crypto prices perform well when the Fed and other central banks cut interest rates. Not this time... the latest crypto crash is bucking the trend.

Bitcoin, Ethereum in the green as Fed gears up for interest rate decision

2025/12/10 05:08
3 min read
For feedback or concerns regarding this content, please contact us at [email protected]

The Federal Reserve’s final meeting of 2025 kicked off on Tuesday, Dec. 9, with the central bank expected to announce its last monetary policy decision of the year at 2:00 p.m. ET on Wednesday.

Summary
  • The Fed is expected to announce a 0.25% rate cut on Wednesday, marking its third reduction of 2025.
  • Historically, Bitcoin tends to rally after rate cuts.
  • Despite volatility, both Bitcoin and Ethereum showed positive movement ahead of the announcement.

Investors are anticipating a 0.25% rate cut, marking the third such reduction of the year, with data from the CME Group showing a 90% probability of the cut.

Polymarket gamblers also lean toward a 0.25% rate reduction, driven by ongoing concerns about the labor market. See below.

Odds of Fed cut are rising

Historically, Bitcoin has reacted positively to rate cuts, as lower interest rates make non-yielding assets like the cryptocurrency more attractive, often weakening the dollar in the process.

However, recent market reactions have been more mixed, with Bitcoin and other assets showing initial dips after cuts in 2025, suggesting that investors are increasingly focused on Fed communications, particularly Jerome Powell’s tone, and broader liquidity conditions rather than just the rate change itself.

Despite the volatility, Bitcoin and Ethereum were both showing positive movement at last check, with analysts predicting that further cuts in late 2025 or early 2026 could lead to rallies despite the current market turbulence.

Ethereum chart

At last check Tuesday, at about 4 p.m. EST, Bitcoin was up about 2.6% for the day. Ethereum was up about 6%. In contrast, altcoins (as of midday Tuesday) were in the red. See below.

Top laggards in the ongoing crypto market pullbackTop laggards in the ongoing crypto market pullback | Source: CMC

Stablecoin outflows 

Data compiled by Nansen shows that the balance of stablecoins in exchanges has plunged to $86 billion, its lowest level since October. They have been in a freefall after peaking at $94 billion on Nov. 6 this year, a sign that investors have embraced a risk-off sentiment.

Stablecoin inflows and outflows Stablecoin inflows and outflows | Source: Nansen

The ongoing stablecoin trends have coincided with the market’s deleveraging. Data compiled by CoinGlass shows that the futures open interest fell by 0.3% in the last 24 hours to $130 billion. 

Falling futures open interest and a flattened funding rate are signs of weak demand in the futures market, which recently dominated the crypto trading industry. 

Federal Reserve interest rate decision ahead 

There is a likelihood that Bitcoin and other altcoins will drop after the cut for three main reasons.

  • First, the interest rate cut has been priced in by market participants, meaning that investors may sell the news.
  • Second, the Fed may deliver a hawkish interest rate cut, signaling that it will hold rates steady for a while as it monitors incoming data.
  • Third, a rate cut may trigger inflation in the U.S., prompting the Fed to either keep rates steady for a while or even hike them in 2026. This fear explains why US bond yields have risen over the past few weeks, with the 10-year yield rising to 4.18%.

The ongoing crypto market pullback confirms out warning on Monday that the rally was likely a dead-cat bounce, a situation where an asset in a free fall rises and then resumes the downtrend.

Market Opportunity
Notcoin Logo
Notcoin Price(NOT)
$0.0003688
$0.0003688$0.0003688
+2.41%
USD
Notcoin (NOT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09